Proton (1H) MR spectroscopy of the breast
Proton (1H) MR spectroscopy of the breast
复制标题
DOI：
10.1148/rg.27si075504
复制
发表时间：
2007-10-01
期刊：
影响因子：
5.5
通讯作者：
Huang, Wei
中科院分区：
文献类型：
--
作者：
Bartella, Lia;Huang, Wei
质子（氢 1）[H-1]）磁共振 (MR) 光谱提供有关所研究组织的生化信息。它在癌症中的诊断价值通常基于检测胆碱化合物水平升高，胆碱是活动性肿瘤的标志物。 1H MR 波谱的两个主要潜在临床应用是 (a) 作为乳腺 MR 成像的辅助手段，以提高区分良性和恶性病变的特异性，以及 (b) 用于监测甚至预测接受新辅助化疗的患者的治疗反应。初步数据令人鼓舞，研究结果表明 1H MR 光谱可能会减少根据 MR 成像结果推荐的良性活检数量，并可能有助于预测第一剂新辅助化疗后 24 小时内的反应。尽管目前存在一些限制，使得该技术在临床上应用还为时过早，但肯定需要进行更大规模、最好是多中心试验的进一步评估。
Proton ( hydrogen 1) [H-1]) magnetic resonance ( MR) spectroscopy provides biochemical information about the tissue under investigation. Its diagnostic value in cancer is typically based on the detection of elevated levels of choline compounds, choline being a marker of active tumor. The two main potential clinical applications of 1H MR spectroscopy are ( a) as an adjunct to breast MR imaging to improve specificity in differentiating benign from malignant lesions, and ( b) for monitoring or even predicting response to treatment in patients undergoing neoadjuvant chemotherapy. Preliminary data are promising, with study results suggesting that 1H MR spectroscopy may decrease the number of benign biopsies recommended on the basis of MR imaging findings and may help predict response as early as 24 hours after the first dose of neoadjuvant chemotherapy. Although several limitations currently exist that make the technique premature for clinical use, further evaluation with larger, preferably multicenter trials is certainly warranted.